文献
(901～946)901. Evangelista LS, Sackett E, Dracup K. Pain and heart failure: unrecognized and untreated. Eur J Cardiovasc Nurs 2009; 8: 169-173. PMID:
19150255
902. Schaefer KM, Shober Potylycki MJ. Fatigue associated with congestive heart failure: use of Levine’s Conservation Model. J Adv Nurs
1993; 18: 260-268. PMID: 8436716
903. Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch
Intern Med 2007; 167: 367-373. PMID: 17325298
904. Fosbøl EL, Gislason GH, Poulsen HE, et al. Prognosis in heart failure and the value of β-blockers are altered by the use of
antidepressants and depend on the type of antidepressants used. Circ Heart Fail 2009; 2: 582-590. PMID: 19919983
905. May HT, Horne BD, Carlquist JF, et al. Depression after coronary artery disease is associated with heart failure. J Am Coll Cardiol 2009;
53: 1440-1447. PMID: 19371828
906. Angermann CE, Gelbrich G, Störk S, et al. MOOD-HF Study Investigators and Committee Members. Effect of Escitalopram on All-Cause
Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA 2016;
315: 2683-2693. PMID: 27367876
907. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007; 120: 799-806. PMID:
17765050
908. Tu RH, Zeng ZY, Zhong GQ, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-
analysis of randomized controlled trials. Eur J Heart Fail 2014; 16: 749-757. PMID: 24797230
909. Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable
electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12: 1480-1489. PMID: 20675674
910. 補助人工心臓治療関連学会協議会．我が国における植込型補助人工心臓適応適正化の考え方：Destination Therapy について．
911. Swetz KM, Kamal AH, Matlock DD, et al. Preparedness planning before mechanical circulatory support: a “how-to” guide for palliative]
medicine clinicians. J Pain Symptom Manage 2014; 47: 926-935.e6. PMID: 24094703
912. 日本救急医学会，日本集中治療医学会，日本循環器学会．救急・集中治療における終末期医療に関するガイドライン～ 3学会からの提言～．
913. Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised
placebo-controlled study. Lancet 2010; 376: 875-885.PMID: 20801500
914 Tsutsui H, Momomura S, Yamashina A, et al. study investigators. Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients
With Chronic Heart Failure - A Randomized, Double-Blind, Placebo- Controlled Phase II Study. Circ J 2016; 80: 668-676. PMID:
26763489
915. Vodovar N, Paquet C, Mebazaa A, et al. Neprilysin, cardiovascular, and Alzheimer’s diseases: the therapeutic split? Eur Heart J 2015;
36: 902-905. PMID: 25636748
916. Tsutsui H, Momomura S, Saito Y, et al. Efficacy and safety of sacubitril/ valsartan (LCZ696) in Japanese patients with chronic heart failure
and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol 2017; 70:
225-231. PMID: 28024961
917. Gheorghiade M, Marti CN, Sabbah HN, et al. Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a potential
therapeutic target for heart failure. Heart Fail Rev 2013; 18: 123- 134. PMID: 22622468
918. Greenberg B. Novel Therapies for Heart Failure - Where Do They Stand? Circ J 2016; 80: 1882-1891. PMID: 27545139
919. Nossaman B, Pankey E, Kadowitz P. Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic
indications. Crit Care Res Pract 2012; 2012: 290805. PMID: 22482042
920. Pieske B, Butler J, Filippatos G, et al. SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate
Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 2014; 16: 1026-1038. PMID: 25056511
921. Gheorghiade M, Greene SJ, Butler J, et al. SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble
Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection
Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 2015; 314: 2251-2262. PMID: 26547357
922. A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA).
923. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011;
331: 1439-1443. PMID: 21415352
924. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin
activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011; 378: 667-675. PMID: 21856480
925. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic
heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-683. PMID:21856481
926. Teerlink JR, Felker GM, McMurray JJV, et al. ATOMIC-AHF Investigators. Acute Treatment With Omecamtiv Mecarbil to Increase
Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol 2016; 67: 1444-1455. PMID: 27012405
927. Teerlink JR, Felker GM, McMurray JJ, et al. COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility
in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 2016; 388: 2895-2903.
PMID: 27914656
928. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on
Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF).
929. Feldman T, Kar S, Elmariah S, et al. EVEREST II Investigators. Randomized Comparison of Percutaneous Repair and Surgery for Mitral
Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol 2015; 66: 2844-2854. PMID: 26718672
930. Puls M, Lubos E, Boekstegers P, et al. One-year outcomes and pre dictors of mortality after MitraClip therapy in contemporary clinical
practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 2016; 37: 703-712. PMID: 26614824
931. Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. J
Am Coll Cardiol 2016; 67: 1129-1140. PMID: 26965532
932. Sawa Y, Miyagawa S. Present and future perspectives on cell sheetbased myocardial regeneration therapy. Biomed Res Int 2013; 2013:
583912. PMID: 24369013
933. Yoshikawa Y, Miyagawa S, Toda K, et al. Myocardial regenerative therapy using a scaffold-free skeletal-muscle-derived cell sheet in
patients with dilated cardiomyopathy even under a left ventricular assist device: a safety and feasibility study. Surg Today 2018; 48: 200-
210. PMID: 28821963
934. Miyagawa S, Domae K, Yoshikawa Y, et al. Phase I Clinical Trial of Autologous Stem Cell-Sheet Transplantation Therapy for Treating
Cardiomyopathy. J Am Heart Assoc 2017; 6: e003918. PMID:28381469
935. Sawa Y, Yoshikawa Y, Toda K, et al. Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of
Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J 2015; 79: 991-999. PMID: 25912561
936. Tei C. Waon therapy: soothing warmth therapy. J Cardiol 2007; 49: 301-304. PMID: 17633566
937. Tei C, Tanaka N. Thermal vasodilation as a treatment of congestive heart failure: a novel approach. J Cardiol 1996; 27: 29-30. PMID:
8683432
938. Miyata M, Kihara T, Kubozono T, et al. Beneficial effects of Waon therapy on patients with chronic heart failure: results of a prospective
multicenter study. J Cardiol 2008; 52: 79-85. PMID: 18922381
939. Sobajima M, Nozawa T, Fukui Y, et al. Waon therapy improves quality of life as well as cardiac function and exercise capacity in patients
with chronic heart failure. Int Heart J 2015; 56: 203-208. PMID:25740582
940. Kisanuki A, Daitoku S, Kihara T, et al. Thermal therapy improves left ventricular diastolic function in patients with congestive heart failure:
a tissue doppler echocardiographic study. J Cardiol 2007; 49: 187-191. PMID: 17460879
941. Kihara T, Biro S, Imamura M, et al. Repeated sauna treatment improves vascular endothelial and cardiac function in patients with
chronic heart failure. J Am Coll Cardiol 2002; 39: 754-759. PMID: 11869837
942. Fujita S, Ikeda Y, Miyata M, et al. Effect of Waon therapy on oxidative stress in chronic heart failure. Circ J 2011; 75: 348-356. PMID:
21173495
943. Kuwahata S, Miyata M, Fujita S, et al. Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure.
J Cardiol 2011; 57: 100-106. PMID: 20884178
944. Kihara T, Biro S, Ikeda Y, et al. Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ
J 2004; 68: 1146-1151. PMID: 15564698
945. Kihara T, Miyata M, Fukudome T, et al. Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol 2009; 53:
214-218. PMID: 19304125
946. Tei C, Imamura T, Kinugawa K, et al. WAON-CHF Study Investigators. Waon Therapy for Managing Chronic Heart Failure - Results
From a Multicenter Prospective Randomized WAON-CHF Study. Circ J 2016; 80: 827-834. PMID: 27001189
急性･慢性心不全診療ガイドライン（2017年改訂版）
Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure
（JCS 2017/JHFS 2017）